New combo therapy aims to beat back relapsed leukemia after transplant

NCT ID NCT06529731

Recruiting now Disease control Sponsor: Sawa Ito, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This phase 2 trial tests whether combining interferon-gamma (a protein that boosts the immune system) with donor immune cells can help patients whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The study will enroll 45 adults and measure how long they stay free of relapse or death. Researchers will also study leukemia cells before and after treatment to understand how the therapy works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interferon gamma-1b (a protein that boosts immune activity) and donor leukocyte infusion (immune cells from the original stem cell donor)
What this could lead to: If successful, this combination could offer a new treatment option for patients whose leukemia returns after a stem cell transplant, potentially improving survival without the need for additional intensive chemotherapy.
What could go wrong: This is a small phase 2 trial with only 45 participants, so results may not apply to everyone. The treatment may cause side effects like flu-like symptoms or worsen graft-versus-host disease, and it may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.